Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Mainz – page 26

604 clinical trials in Mainz, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Mainz at a glance
604
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

604 trials in Mainz

Open in trial search

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of Tanimilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tanimilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Chronic obstructive pulmonary disease

Not recruiting

Study on the Effectiveness and Safety of CHF6001 DPI with Roflumilast for Patients with Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Roflumilast
  • Sponsor:Chiesi Farmaceutici S.p.A.

Metabolic dysfunction-associated steatohepatitis+1

Not recruiting

Study on the Effectiveness and Safety of Lanifibranor for Adults with Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis Stages F2/F3

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lanifibranor
  • Sponsor:Inventiva

Dermatitis atopic

Not recruiting

Study on the Long-Term Safety and Efficacy of Nemolizumab for Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Coeliac disease

Not recruiting

Study on the Effects of Amlitelimab for Adults with Non-Responsive Celiac Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neurodermatitis

Not recruiting

Study on the Long-Term Safety and Effectiveness of Nemolizumab for Patients with Prurigo Nodularis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nemolizumab
  • Sponsor:Galderma S.A.

Ovarian cancer

Not recruiting

Study on the Effectiveness of Durvalumab, Olaparib, and Bevacizumab in Patients with Newly Diagnosed Advanced Ovarian Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study of dupilumab added to inhaled corticosteroids and long-acting beta-agonists compared to high-dose inhaled therapy in adolescents and adults with uncontrolled asthma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Chronic spontaneous urticaria

Not recruiting

Study on Barzolvolimab for Patients with Chronic Spontaneous Urticaria Unresponsive to H1 Antihistamines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.

Gastric cancer+1

Not recruiting

Study on Durvalumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study on Long-Term Safety of Depemokimab for Adults and Adolescents with Severe Eosinophilic Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Chronic kidney disease

Not recruiting

Study on the Effects of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease and High Protein Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Mainz

What the registry says about research in the country

01 Infectious Disease Prevention

Groundbreaking trials focusing on viral infections including studies of vaccines against Respiratory Syncytial Virus, Herpes Zoster, and Cytomegalovirus. Research aims to evaluate vaccine efficacy and immune response in different age groups.

  • RSV and hMPV Prevention
  • Herpes Zoster Protection
  • CMV Vaccine Development

Special attention is given to protecting vulnerable populations, including older adults and those at increased risk.

02 Oncology Research

Innovative clinical trials targeting various forms of cancer, including studies on breast cancer, pancreatic cancer, and multiple myeloma. Research focuses on novel therapeutic approaches and combination treatments.

  • Advanced Breast Cancer Therapy
  • Gastric Cancer Treatment
  • Lymphoma Management

Emphasis on personalized medicine approaches and targeted therapies for better patient outcomes.

03 Chronic Disease Management

Comprehensive studies addressing respiratory conditions, autoimmune disorders, and metabolic diseases. Research includes treatments for asthma, multiple sclerosis, and obesity.

  • Pulmonary Hypertension
  • Chronic Kidney Disease
  • Autoimmune Conditions

Focus on developing long-term treatment solutions and improving quality of life for patients.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.